Neratinib and Trastuzumab Biosimilar in Patients With HER2 Mutated Advanced Solid Cancers

• Sponsor: Korea University Guro Hospital (Other)
• Overall Status: Active, not recruiting
• CT.gov ID: NCT06083662
• Collaborator: Korean Cancer Study Group (Other)
• Enrollment: 42
• Location: 1
• Arm: 1
• Anticipated Duration (Months): 36.5
• Patients Per Site Per Month: 1.2

Study Details

Study Description

Brief Summary

Prospective, Basket, Open-label, Multi-dose, Single-arm, Simon's two-stage, Multi-center trial

Study drug : neratinib + herzuma (trastuzumab biosimilar)

Condition or Disease	Intervention/Treatment	Phase
Metastatic Cancer; HER2 Gene Mutation	Drug: Neratinib Maleate	Phase 2

Detailed Description

1. Primary objective Evaluate overall response rate (ORR) in HER2 mutated advanced solid cancer patients based on RECIST v1.1

2. Secondary objectives

(1) Evaluate clinical benefit rate (CBR) (2) Evaluate duration of response (DOR) (3) Evaluate progression free survival (PFS) (4) Evaluate overall survival (OS) (5) Evaluate compliance with oral administration 3) Safety evaluation

1. Evaluate the overall safety of the test drug

2. Evaluate the predefined adverse event (diarrhea)

Study Design

• Study Type: Interventional
• Actual Enrollment: 42 participants
• Allocation: N/A
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: Phase II Basket Trial to Evaluate Safety and Efficacy of Neratinib, An Irreversible Tyrosine Kinases Inhibitor of EGFR, ERBB2 and ERBB4 Receptors and Trastuzumab Biosimilar (Herzuma®) in Patients With HER2 Mutated Advanced Solid Cancers
• Actual Study Start Date: Jun 15, 2021
• Anticipated Primary Completion Date: Nov 30, 2023
• Anticipated Study Completion Date: Jun 30, 2024

Arms and Interventions

Arm	Intervention/Treatment
Experimental: A arm Neratinib + herzuma	Drug: Neratinib Maleate; neratinib 240mg po daily herzuma 8mg/kg (loading) --> 6mg/kg q3w; Other Names: Herzuma

Outcome Measures

Primary Outcome Measures

1. overall response rate (ORR) [at 6 months]

   ORR according to RECIST v1.1

Secondary Outcome Measures

1. clinical benefit rate, CBR [at 6 months]

   CR+PR + SD more than 12 weeks

2. median duration of response, DOR [at 6 months]

   DOR is related to the quality of life and is one of the methods for evaluating tumor response approved by pharmaceutical regulatory agencies

3. median progression free survival, PFS [at 6 months]

   from enrollment to disease progression, death or withdrawal

4. safety profiles [at 6 months]

   safety profiles according to CTCAE 4.0

Eligibility Criteria

Criteria

• Ages Eligible for Study: 19 Years and Older
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Inclusion Criteria:

• Patients who voluntarily decide to participate and give written consent after hearing the explanation of the clinical trial and investigational drugs.

• Adult men and women over 19 years old.

• Histological or cytological confirmed advanced solid tumor and confirmed to have HER2 known oncogenic mutations in tumor DNA by K-master panel test using tumor tissues or circulating tumor DNA in blood.

• Patients having at least 1 or more than 1 measurable lesion according to RECIST v 1.1.

• Eastern Cooperative Oncology Group (ECOG) performance status 0~2.

• Patients whose life expectancy is more than 6 months.

• Metastatic/progressive solid cancer patients who have received one or more than one standard treatment or do not have any treatment option.

• Patients who have agreed to provide plasma/blood samples, the most recent metastatic/progressive tumor sample or new tumor biopsy for gene sequencing and other biomarker analysis.

Exclusion Criteria:

• Patients who received radiotherapy or surgical treatment within 2 weeks prior to the initiation of investigational product.

• Patients having symptomatic brain metastasis who needs treatment. Patients with stable brain metastasis who need no treatment including steroid are eligible

• Inappropriate HER2 mutation (e.g., non-Hot Spot mutation, variant of unknown siginificance, subclonal mutation, premature STOP codon or the Frame Shift mutation).

• Patients having difficulties in swallowing tablets.

• Patients with toxicities of prior treatment which are not recovered to baseline level or ≤ Grade 1.

• Inadequate organ functions:

1. Hemoglobin (Hemoglobin) < 8 .0g / dL

2. Absolute neutrophil count (ANC) < 1. 0 x10 ³ per mm³

3. Platelet count < 100 x10⁹/L (100 ,000/ mm³)

4. Total bilirubin > 1.5 x upper normal limits (UNL), (exclude Gilbert's syndrome)

5. Alanine aminotransferase (ALT) or aspartate amino transferase (AST) > 3 x upper normal limits (UNL) (in case of liver and bone metastases > 5 x ULN)

6. Serum creatinine >1.5 x upper normal limits (UNL) or < eGFR 30 mL/min/1.73 m² 7) Left ventricle ejection fraction <50% by multi-gate obtaining method scan (MUGA) or echocardiogram.

1. Chronic gastrointestinal disorders of which a main symptom is diarrhea (e.g., Crohn's disease, malabsorption, or grade 2 or more than grade 2 diarrhea according to the NCI CTCAE version 5.0 regardless of etiology).

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Korea university Guro hospital	Seoul		Korea, Republic of

Sponsors and Collaborators

• Korea University Guro Hospital
• Korean Cancer Study Group

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: Park, In Hae, MD, PhD, Korea University Guro Hospital
• ClinicalTrials.gov Identifier: NCT06083662
• Other Study ID Numbers: AL20-17
• First Posted: Oct 16, 2023
• Last Update Posted: Oct 20, 2023
• Last Verified: Oct 1, 2023

• Individual Participant Data (IPD) Sharing Statement: No
• Plan to Share IPD: No
• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No
• Additional relevant MeSH terms: Neoplasm Metastasis; Maleic acid

Study Results

No Results Posted as of Oct 20, 2023